Oculis Announces FDA IND Clearance Enabling Acceleration of Privosegtor Development Program in Acute Multiple Sclerosis Relapses
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Oculis (OCS) received FDA clearance to begin clinical development of Privosegtor for acute multiple sclerosis relapses under an Investigational New Drug application.
The FDA supported a proposed strategy covering optic neuritis and other relapses, including ambulatory relapses, with a primary endpoint as early as three months and dosing of 3 mg/kg daily for five days. Oculis can cross-reference data from its existing ophthalmology-related application.
The completed Phase 2 ACUITY trial enrolled optic neuritis patients with and without MS. It showed improved visual function, preserved retinal ganglion cell layer integrity and reduced blood markers of nerve-fiber injury and supporting-cell activation. No adverse events led to drug withdrawal or study discontinuation. Oculis plans to discuss the acute MS relapse development program and ongoing PIONEER program at an R&D Day on December 8, 2026.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate pointFDA clearance enables Privosegtor clinical development in acute multiple sclerosis relapses.
- Moderate point. Forward-looking: it has not happened yet and may not happen.FDA-supported proposed strategy includes optic neuritis and other relapses, with a primary endpoint as early as three months.
- Minor pointCross-referencing existing ophthalmology IND data is permitted for the acute MS relapse development program.
- Minor pointPhase 2 ACUITY showed improved visual function in optic neuritis patients with and without MS.
- Minor pointRetinal ganglion cell layer integrity was preserved in the completed Phase 2 ACUITY trial.
2 minor points
- Minor pointBlood biomarkers of nerve-fiber injury and supporting-cell activation declined in Phase 2 ACUITY.
- Minor pointACUITY safety findings included no adverse events leading to drug withdrawal or study discontinuation.
Negative
- None.
Key Figures
- Dose regimen
- 3 mg/kg daily for five days
- Proposed clinical development strategy, using the PIONEER-1 regimen
- Primary endpoint timing
- as early as three months
- Proposed clinical development strategy supported by the FDA
Previous Clinical trial Reports
-
ACUITY biomarker findings showed lower nerve-injury and inflammation markers with Privosegtor versus placebo.
-
Phase 2 ACUITY reported visual gains and retinal preservation with Privosegtor in optic neuritis.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
investigational new drug (ind) application regulatory
primary endpoint medical
neurofilament light chain medical
glial fibrillary acidic protein medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
FDA IND clearance opens a new era for Oculis in neurology, initiating clinical development in acute MS relapses by building directly upon the positive Phase 2 ACUITY trial and ongoing PIONEER program in optic neuritis
Oculis will host an R&D Day on December 8, 2026, to provide further updates on the development program for Privosegtor in acute MS relapses and the ongoing PIONEER program in optic neuropathies
ZUG, Switzerland, November 16, 2026 -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough innovations to address critical unmet medical needs in neuro-ophthalmology, neurology, and ophthalmology, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for Privosegtor for the treatment of acute multiple sclerosis (MS) relapses.
The FDA clearance follows pre-IND feedback from the FDA Division of Neurology-2, which confirmed that Oculis can cross-reference data from the open Privosegtor ophthalmology-related IND. The FDA further supported the proposed clinical development strategy, which would include patients with Multiple Sclerosis (MS) who experience Optic Neuritis (ON) as well as other types of relapses, such as ambulatory relapses, and a primary endpoint as early as three months, using the same 3mg/kg daily dose for five days as in PIONEER-1.
Optic neuritis is frequently observed both as the initial clinical presentation of MS and during acute relapses, serving as a pathophysiological model of acute demyelination that is potentially generalizable to other acute MS relapses. In the completed Phase 2 ACUITY study, which evaluated a broad population of patients with ON, including those with and without MS, Privosegtor demonstrated a promising neuroprotective effect. Specifically, it improved visual function, preserved retinal ganglion cell (RGC) layer integrity, and reduced blood levels of both neurofilament light chain (NfL), a biomarker of axonal injury, and glial fibrillary acidic protein (GFAP), a biomarker of astrocytic activation.
Building on these positive findings, expanding into acute MS relapses is a natural evolution for the Privosegtor program. MS affects approximately 2.8 million people worldwide¹, with an estimated 170,000 relapses occurring annually in the U.S. alone⁷, representing both a significant clinical opportunity and a critical unmet need. While every relapse carries the risk of permanent nerve damage, current standard-of-care immunomodulators or disease-modifying therapies only shorten attack duration or reduce relapse frequency. Privosegtor has the potential to become the first neuroprotective therapy to actively preserve nerve integrity during acute MS relapses.
“This IND clearance marks a pivotal new era for Oculis in neurology as we advance Privosegtor from optic neuritis into acute MS relapses, addressing a high-unmet-need setting with no currently approved neuroprotective therapies," said Dr. Riad Sherif, Chief Executive Officer of Oculis. "Because optic neuritis is a common manifestation of MS relapse, our positive Phase 2 ACUITY results give us confidence in Privosegtor’s potential to limit neuroaxonal damage and support functional recovery following an acute attack. Building on the foundation of our PIONEER registrational program in optic neuritis, we are well-positioned to accelerate the clinical development of Privosegtor in this new indication. We value the FDA’s constructive engagement and are excited about the meaningful impact Privosegtor could have on patients experiencing optic neuritis and other MS relapses.”
Amit Bar-Or, MD, Professor of Neurology at the Perelman School of Medicine, University of Pennsylvania, said: “Even with effective immunomodulating therapies, many people with MS still experience relapses, and recovery from them is often incomplete. A treatment that protects neurons and axons during an acute relapse would fill a gap that no current care addresses. I am encouraged to see Privosegtor moving toward clinical development in acute MS relapses and beyond and look forward to seeing how the data evolve.”
Oculis plans to host an R&D Day on December 8, 2026, to review additional details on the PIONEER program, including the pivotal development program for Privosegtor in acute MS relapses, and provide a comprehensive update on the PIONEER program in optic neuropathies and Acute MS relapse. To register for the event, click here.
- Ends -
About Oculis
Oculis is a global biopharmaceutical company (Nasdaq: OCS; XICE: OCS) focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology, neurology, and ophthalmology. Oculis’ highly differentiated late-stage clinical pipeline focuses on two core product candidates. Privosegtor is a breakthrough neuroprotective candidate in the PIONEER program, designed to support registrational plans across optic neuropathies, such as optic neuritis (ON) and NAION, as well as acute MS relapses. Privosegtor also offers potential for expansion into additional neuro-ophthalmic and neuro-axonal indications. Licaminlimab is a novel topical anti-TNFα in a registrational trial and is being developed with a genotype-based approach to treat patients with TNFR1 dry eye disease. Headquartered in Switzerland with operations in the U.S. and Europe, Oculis is led by an experienced management team with a successful track record and supported by leading international healthcare investors.
For more information, please visit: www.oculis.com
About Privosegtor
Privosegtor, a novel peptoid small-molecule candidate that crosses the blood-brain and retinal barriers, has the potential to become the first neuroprotective therapy for optic neuritis (ON) and other neuro-ophthalmic and neuro-axonal diseases. Positive results from the ACUITY Phase 2 trial showed Privosegtor’s neuroprotective potential, as evidenced by improvements in visual function, corroborated by anatomical preservation of the retina, including GCIPL and RNFL layers, and reduced neurofilament levels in the blood after an acute episode of optic neuritis. Furthermore, the safety profile reported in the ACUITY Phase 2 trial showed no adverse events leading to drug withdrawal or study discontinuation. Consistent results were observed in animal models of glaucoma, optic neuritis and multiple sclerosis, where Privosegtor preserved retinal ganglion cells and was associated with improvements in mobility in the multiple sclerosis model.
Privosegtor has received Breakthrough Therapy designation from the U.S. Food and Drug Administration and Priority Medicines (PRIME) designation from the European Medicines Agency, as well as Orphan Drug designation from both agencies for ON. Privosegtor is currently being evaluated in Oculis’ PIONEER (Privosegtor Investigation in Optic Neuropathies Efficacy Evaluation Research) program, which includes two registrational trials in ON and one registrational trial in non-arteritic anterior ischemic optic neuropathy.
Privosegtor is an investigational drug and has not received regulatory approval for commercial use in any country.
About Multiple Sclerosis (MS)
MS is a chronic autoimmune disease of the central nervous system (CNS) which targets the myelin sheath of axons and the axons themselves, affecting approximately 2.8 million people worldwide1, including around 850,000 in the U.S. alone.2-6 The most common form, relapsing-remitting MS (RRMS), accounts for approximately
Current treatment of acute MS relapses primarily relies on high-dose corticosteroids to reduce inflammation and shorten the episode, while immunomodulator therapies help reduce relapse frequency. However, neither approach has been proven to directly protect neurons and axons from injury during acute inflammatory events. Tissue injury and the neuroinflammatory toxic microenvironment occurring during relapses can contribute to neuroaxonal loss and the accumulation of functional disability over time, underscoring the need for therapies that protect neurons and axons during relapses.2,8 Despite advances in the long-term management of MS, a significant unmet need remains for therapies that provide neuroprotection during acute relapses, preserve neurological tissues, reduce the risk of functional disability over time and improve the likelihood of optimal recovery.9,10
Contacts
Oculis Contact
Ms. Sylvia Cheung, CFO
sylvia.cheung@oculis.com
Investor Relations
Mr. Terence McManus
terence.mcmanus@oculis.com
Media Relations
ICR Healthcare
Amber Fennell / David Daley / Sean Leous
oculis@icrhealthcare.com
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements and information. For example, statements regarding the potential benefits of the Company’s product candidates, including the potential for Privosegtor to become the first neuroprotective therapy for optic neuritis and other neuro-ophthalmic and neuro-axonal diseases and the potential applicability of ACUITY ON results to an acute MS relapse indication; the potential for Licaminlimab to transform the treatment paradigm in dry eye disease with a precision medicine approach; the design, initiation, enrollment, timing, progress and results of current and future clinical trials; Oculis’ research and development programs, regulatory and business strategy; Oculis’ future development plans; the timing or likelihood of regulatory filings and approvals; and statements about market opportunity, are forward-looking. All forward-looking statements are based on estimates and assumptions that, while considered reasonable by Oculis and its management, are inherently uncertain and subject to risks, variability and contingencies, many of which are beyond Oculis’ control. Results from prior clinical trials may not be replicated in later clinical trials. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, assurance, prediction or definitive statement of a fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. All forward-looking statements are subject to risks, uncertainties and other factors that may cause actual results to differ materially from those expected and/or expressed or implied by such forward-looking statements, including those set forth in the Risk Factors section of Oculis’ annual report on Form 20-F and any other documents filed with the U.S. Securities and Exchange Commission. Oculis undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.
References:
- Filippi M, et al. Nat Rev Dis Primers. 2018
- McGinley et al., 2021, Diagnosis and Treatment of Multiple Sclerosis: A Review – PubMed
- Tjalf Ziemssen, et al. Neurol Neuroimmunol Neuroinflamm 2023;10:e200064
- National MS Society website: https://www.nationalmssociety.org/
- Wallin et al., 2019, The prevalence of MS in the United States: A population-based estimate using health claims data – PubMed
- Hittle M, et al. JAMA Neurol. 2023 Jul 1;80(7):693-701.
- Relapse volume derived as ARR 0.2 × ~850,000 U.S. MS prevalence (Hauser SL, et al. N Engl J Med. 2020;383:546-557, Bigaut K, et al. J Neurol. 2022 Jun;269(6):3295-3300).
- Ramo-Tello C, et al. J Pers Med. 2021; 12:6
- Antel JP, et al. J Clin Invest. 2023; 133:e168595;
- Ladeira F, et al. Mult Scle Relat Disord. 2025; 106507
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.